NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its preliminary fourth quarter revenues grew between 61 percent and 65 percent, largely due to sales of Olerup HLA typing-branded products following the acquisition of Allenex AB in April 2016.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.